Manufactures and sells pharmaceutical drugs and formulations, which generated 99.1% of segment revenue (Rs. 512.74 crore) in FY26, with a segment EBIT of Rs. 98.66 crore. A small renting-of-property line contributed 0.7% of segment revenue (Rs. 3.70 crore, EBIT Rs. 3.00 crore), and commodity trading contributed 0.2% (Rs. 1.10 crore, near-breakeven). For FY26, consolidated revenue from operations stood at Rs. 489.17 crore with a net profit of Rs. 76.44 crore and EBITDA margin of 22.2%. The cost structure is dominated by materials at 45.2% of revenue, followed by employee cost at 13.7%, other operating expenses at 12.3%, depreciation at 1.3%, and capex at 2.4% of revenue. The company reported a sharp YoY profit jump in FY26, with PAT rising roughly 55% on consolidated basis, even as Q3 FY26 revenue dipped about 9.8% YoY. During FY26, the company purchased the entire 7th floor of Trade Star building on Andheri-Kurla Road, Mumbai, from HDFC Bank for Rs. 57.26 crore, and is contesting a Rs. 1.41 crore GST demand notice. AR · MarketPing reader · 2026-08-02
Revenue streams, as the annual report describes them. Pharmaceuticals Drugs & Formulations (99%), Renting of Property (1%), Trading of Commodities (0%). Pharmaceutical formulations manufacturer with a small property rental side-business
| ₹ crore · consolidated | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| Revenue | 224 | 263 | 465 | 489 |
| EBITDA (ex other income) | 20 | 30 | 54 | 77 |
| margin % | 8.8 | 11.2 | 11.6 | 15.8 |
| Owners' profit | 0 | 25 | 0 | 0 |
| EPS, as reported (₹) | 0.24 | 0.34 | 0.57 | 0.81 |
| ROE % · ROCE % | 7.8 · 11.2 | 8.8 · 12.9 | 14.4 · 18.8 | 18.4 · 23.8 |
| Debt / equity (x) | 0.32 | 0.25 | 0.01 | 0.00 |
| Cash from operations | 11 | (6) | 23 | 58 |
| Capex | (21) | (8) | (10) | (12) |
| ₹ crore | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 102 | 128 | 149 | 117 | 122 | 115 | 135 | 126 |
| Profit before tax | 15 | 17 | 23 | 20 | 22 | 25 | 34 | 32 |
| Net profit | 11 | 13 | 18 | 16 | 17 | 19 | 25 | 25 |
| EPS (₹) | 0.16 | 0.14 | 0.16 | 0.21 | 0.18 | 0.23 | 0.27 | 0.26 |
| Segment | Revenue, ₹ crore | Share % |
|---|---|---|
| Pharmaceuticals Drugs & Formulations | 275 | 52.8 |
| Trading of Commodities | 1 | 0.2 |
| Renting of Property | 2 | 0.4 |
| PHARMACEUTICALS DRUGS AND FORMULATIONS | 120 | 23.0 |
| TRADING OF COMMODITIES | 0 | 0.0 |
| RENTING OF PROPERTY | 1 | 0.2 |
| Pharmaceuticals Drugs and Formulations | 121 | 23.2 |
| Renting of Properties | 1 | 0.2 |
| Total, before eliminations | 521 | 100.0 |
| Date · filing | Category | Importance | 1-day % | 5-day % |
|---|---|---|---|---|
| 8 Sept 2026 · Syncom submits 38th AGM notice newspaper clippings to BSE and NSE | compliance | minimal | — | — |
| 7 Sept 2026 · Company sends annual report link to shareholders without registered emails | compliance | minimal | — | — |
| 7 Sept 2026 · Syncom Formulations files BRSR for FY 2025-26 with BSE and NSE | compliance | minimal | — | — |
| 7 Sept 2026 · Notice of 38th AGM on September 30, 2026 via video conferencing | board shareholder meetings | low | — | — |
| 7 Sept 2026 · 38th Annual Report and AGM Notice filed; AGM on Sept 30, 2026 | board shareholder meetings | medium | — | — |
| 1 Sept 2026 · Syncom Formulations files 38th AGM notice clippings with BSE and NSE | compliance | minimal | — | — |
| 13 Aug 2026 · Syncom Formulations Q1 FY27: PAT up 58%, income up 8% | compliance | low | — | — |
| 13 Aug 2026 · Founder-Promoter Managing Director resigns from Syncom Formulations | management changes | critical | — | — |
| 13 Aug 2026 · Syncom Formulations: Founder-promoter Whole-Time Director resigns | management changes | high | — | — |
| 12 Aug 2026 · Syncom files Q1 FY27 unaudited results press clipping | compliance | minimal | — | — |
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) | A state: the latest filed quarter and the measured reactions |
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| SUN PHARMACEUTICAL IND L | 4,41,471 | 36.5 | 5.26 | 23.7 | 13.7 | 17.5 | 11.8 | 32.3 |
| DIVI S LABORATORIES LTD | 2,47,033 | 84.6 | 14.74 | 63.7 | 15.3 | 18.8 | 8.7 | 42.8 |
| TORRENT PHARMACEUTICALS L | 1,68,062 | 79.3 | 9.56 | 41.5 | 12.2 | 8.0 | 11.8 | 33.1 |
| ZYDUS LIFESCIENCES LTD | 1,11,686 | 24.9 | 3.78 | 14.5 | 17.3 | 18.0 | 12.4 | 25.2 |
| CIPLA LTD | 1,10,352 | 32.7 | 3.20 | 16.9 | 11.2 | 14.7 | 8.0 | 19.7 |
| LAURUS LABS LIMITED | 1,06,375 | 97.2 | 19.59 | 59.3 | 16.4 | 17.2 | 7.2 | 32.0 |
| DR. REDDY S LABORATORIES | 97,319 | 30.1 | 2.55 | 13.1 | 10.9 | 13.0 | 12.1 | 15.0 |
| AUROBINDO PHARMA LTD | 96,656 | 26.3 | 2.55 | 13.4 | 9.2 | 12.6 | 6.3 | 23.0 |
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 20.9 | 28.9 | 59 of 169 | 66% |
| P/B | 4.4 | 3.3 | 106 of 163 | 35% |
| ROCE | 23.5 | 10.8 | 20 of 183 | 90% |
| ROE | 18.4 | 10.4 | 26 of 171 | 85% |
| Debt / Equity | 0.0 | 0.1 | 46 of 171 | 74% |
| EBITDA margin | 27.1 | 17.5 | 45 of 165 | 73% |
| Revenue growth | 7.4 | 16.3 | 103 of 161 | 36% |
| Profit growth | 57.7 | 30.9 | 58 of 158 | 64% |
| Market cap | 1843 | 839 | 80 of 182 | 56% |
| an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
